Ivosidenib + azacitidine ups event-free survival in IDH1-mutated acute myeloid leukemia

Compared with placebo and azacitidine, the combination of ivosidenib and azacitidine prolongs event-free survival for patients with newly diagnosed IDH1-mutated acute myeloid leukemia who are ineligible for induction chemotherapy, according to a study published in the April 21 issue of the New England Journal of Medicine.
Compared with placebo and azacitidine, the combination of ivosidenib and azacitidine prolongs event-free survival for patients with newly diagnosed IDH1-mutated acute myeloid leukemia who are ineligible for induction chemotherapy, according to a study published in the April 21 issue of the New England Journal of Medicine.